Jurnal Surya Medika (JSM)
metadata only
Perbandingan Keberhasilan Terapi Antivirus Favipiravir dan Remdesivir pada Pasien Covid-19 di RSUD dr. Doris Sylvanus: Comparison the Success of Favipiravir and Remdesivir Antivirus Therapy of Covid-19 Patiens in RSUD Dr. Doris Sylvanus
All drugs used for COVID-19 therapy are circulated under a particular scheme, namely the Emergency Use Authorization (EUA) from the Food and Drug Administration. Considering that this COVID-19 is a new case, the high mortality rate, and the lack of research related to COVID-19 drug therapy in Centra
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- New Antiviral Drugs for Treatment of COVID-19#158058
- Remdesivir from failed Ebola drug to first FDA-approved COVID-19 antiviral: The medico-legal integration.#399831
- Ivermectin In Treatment of COVID 19 Patients#1151016
- Prognosis and Course of COVID-19 Infection in Hospitalised Patients#910829
- Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents#1138121
Record · ID 1003910
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive